Adaptimmune to Initiate Rolling BLA Submission After Lete-cel Success in Sarcoma Study
Adaptimmune's investigational TCR T cell therapy, lete-cel, demonstrated encouraging results in the Phase II IGNYTE-ESO study for patients with advanced synovial sarcoma or myxoid/round cell liposarcoma. The trial revealed a 42% response rate among 64 participants, with complete responses observed in six patients and partial responses in 21, underscoring lete-cel's potential efficacy. Additionally, the median duration of response was reported to be 12.2 months, while progression-free survival was 5.3 months, indicating a tangible benefit in delaying disease progression[1][2].
References
Explore Further
What are the specific mechanisms by which lete-cel achieves its 42% response rate in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma?
How will the strategic $665 million partnership with Galapagos support Adaptimmune in bringing lete-cel to market?
What challenges did Adaptimmune face during the termination of their $3 billion partnership with Genentech?
What impact will the 33% reduction in workforce have on Adaptimmune's long-term operational capabilities?
How does the FDA's recent approval of afami-cel (Tecelra) influence Adaptimmune's strategy for lete-cel's market entry?